Drugs / MLC1501
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04233437 | Feb → May 2020 | stroke disorder | Moleac Pte Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05289947 Comparator | Jul 2023 → Jul 2025 | ischemic stroke, thrombotic disease | Moleac Pte Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05046106 Comparator | Jan 2025 → Sep 2028 expected | intracranial embolism, thrombotic disease | Moleac Pte Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLC1501 | “MLC1501, consisting of four herbs, that is, Radix Astragali, Radix Angelicae sinensis, Rhizoma Chuanxiong, Radix Polygalae” PMID 39915229 ↗ Oct 2025 |
| Modality | Traditional medicine (herbal / TCM) | “Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala” NCT05046106 ↗ |
| Route | Oral | “orally receive MLC1501” NCT05046106 ↗ |